Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07785180 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 9 changed
See other at-risk trials from Stemline Therapeutics, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified
    • Site details revised at 4 of 67 sites
    • Eligibility criteria expanded, about 5 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main goal of this study is to investigate the effectiveness and safety of chemotherapy agents in the treatment of participants with BPDCN and to provide comparator arm data to the prospective ELZONRIS registry study (STML-401-0521).
Trial Details
NCT Number NCT07785180
Lead Sponsor Stemline Therapeutics, Inc.
Conditions
(from sponsor)		 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Related terms Blastic Plasmacytoid Dendritic Cell Neoplasm
Enrollment 140 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov